ERock, Inc.

Erock Inc. jumped 22.84 percent on Wednesday to close at $13.82 after announcing a 470-megawatt equipment order from Anthropic that lifted its contracted power system sales backlog to $1.7 billion and extended production commitments into 2028. The rally came despite a weak second quarter in which net losses ballooned 748 percent to $67.7 million, largely on IPO-related charges, while revenue fell 42 percent to $39.88 million. CEO John Carrington said AI infrastructure is fundamentally reshaping power markets, and the company has begun assembly at its Hyperion facility while starting construction on the 366-megawatt El Paso Electric project for Meta's data center campus. For the full year, Erock is targeting revenue of $435 million to $465 million and adjusted EBITDA of $3 million to $9 million. The company, which listed on June 10, 2026, will face a key test in the third quarter as investors watch whether the Anthropic momentum attracts greater institutional interest.

T-Mobile and Gilead Sciences both received Buy upgrades on Monday, with Bank of America setting a $220 target on T-Mobile and HSBC setting a $155 target on Gilead. Pfizer was downgraded to Hold from Buy at HSBC, which trimmed its target to $28 from $32, while Datadog was cut to Market Perform from Outperform at Bernstein, though its target was raised to $226 from $180. Among other notable calls, Agnico Eagle Mines was upgraded to Buy at Jefferies with a $200 target, Okta was raised to Outperform at Scotiabank with a $165 target, and Delta Air Lines was cut to Outperform from Strong Buy at Raymond James with a target lifted to $104 from $80. New initiations included ERock with Outperform ratings from Evercore ISI and JPMorgan at a $28 target, and Glaukos with a Buy rating at H.C. Wainwright and a $168 target.